

AGENDA
Winter Meeting
National Legislative Association on Prescription Drug Prices
American University Washington College of Law, Washington, D.C

- 9:30 am **REGISTRATION**
- 10:00 am **WELCOME & STATE LEGISLATOR ROUNDTABLE**
Councilmember David Catania, NLARx Board Chair, will moderate a discussion of pending legislative initiatives in the states
- 10:30 am **WHAT’S TRADE GOT TO DO WITH IT?**
The USTR’s New Focus on “Disciplining” Pricing Initiatives, and How State Medicaid Programs and Health Care Reform Could be Negatively Affected
- **Sean Flynn, Esq.**, Associate Director, Program on Information Justice and Intellectual Property, American University’s Washington College of Law
- 11:15 am **SAFEGUARDING KIDS AND CONTAINING PRESCRIPTION DRUG COSTS**
States have experienced 21% increase in spending related to psychiatric drugs purchased through public health programs, and children participating in these programs are prescribed these drugs at higher rates than those with private insurance. These drugs have significant health risks including weight gain, diabetes and movement disorders, and suicidal thoughts. Learn what states are doing to preserve access for those who need them, while monitoring and controlling the prescribing of powerful antipsychotic drugs.
- **Ann Woloson**, Executive Director, Prescription Policy Choices
- 11:45 – 1: 00 LUNCH BREAK – Legislators & staff only business meeting over lunch.**
Presenter: Enzo Pastore, Health Reform Director, Progressive States Network
- 1:00 pm **PANEL ON FEDERAL HEALTH CARE REFORM AND PHARMACEUTICAL POLICY**
What’s the latest on health care reform and changes to pharmaceutical policy? Is change coming anyway, regardless of whether comprehensive reform is voted out this year? Issues include Sunshine Act (gift disclosure), the Part D “donut hole,” price negotiation, PBM reform, data mining, ending “pay to delay” reverse payments, the status of follow-on biologics, and establishing academic detailing.
- **Jill Henderson**, Staff to the Subcommittee on Federal Workforce, Postal Service and the District of Columbia, Committee on Oversight and Government Reform. Ms. Henderson is on detail from The Office of Personnel Management, where she is Deputy Assistant Inspector General for Management.

- **Lance Kilpatrick**, Senior Advisor for Rx Drug Strategies, AARP
- **Jasmin Weaver**, Healthcare Initiatives Legislative Director, Change to Win
- **Sharon Treat**, Executive Director, National Legislative Association on Prescription Drug Prices, Moderator

2:15 pm

WHY ARE DRUG PRICES SO HIGH?

A presentation on the recent GAO Report, “Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases”

- **Meredith Jacob**, Esq., Pharmaceutical Fellow, Program on Information Justice and Intellectual Property, American University’s Washington College of Law

2:45 – 3 pm

WRAP-UP & ADJOURN